329 related articles for article (PubMed ID: 30940695)
1. The Interplay Between Blood Proteins, Complement, and Macrophages on Nanomedicine Performance and Responses.
Moghimi SM; Simberg D; Skotland T; Yaghmur A; Hunter AC
J Pharmacol Exp Ther; 2019 Sep; 370(3):581-592. PubMed ID: 30940695
[TBL] [Abstract][Full Text] [Related]
2. Complement monitoring of nanomedicines and implants.
Moghimi SM; Hunter AC
Adv Drug Deliv Rev; 2011 Sep; 63(12):963-4. PubMed ID: 21745510
[No Abstract] [Full Text] [Related]
3. Plasma protein adsorption on Fe
Escamilla-Rivera V; Solorio-Rodríguez A; Uribe-Ramírez M; Lozano O; Lucas S; Chagolla-López A; Winkler R; De Vizcaya-Ruiz A
Int J Nanomedicine; 2019; 14():2055-2067. PubMed ID: 30988608
[TBL] [Abstract][Full Text] [Related]
4. Complement-dependent uptake of nanoparticles by blood phagocytes: brief overview and perspective.
Li Y; Moein Moghimi S; Simberg D
Curr Opin Biotechnol; 2024 Feb; 85():103044. PubMed ID: 38091875
[TBL] [Abstract][Full Text] [Related]
5. Interaction of nanoparticles with immunocompetent cells: nanosafety considerations.
Boraschi D; Costantino L; Italiani P
Nanomedicine (Lond); 2012 Jan; 7(1):121-31. PubMed ID: 22191781
[TBL] [Abstract][Full Text] [Related]
6. The Nano-War Against Complement Proteins.
Wang Z; Brenner JS
AAPS J; 2021 Sep; 23(5):105. PubMed ID: 34505951
[TBL] [Abstract][Full Text] [Related]
7. Complement activation by drug carriers and particulate pharmaceuticals: Principles, challenges and opportunities.
Moghimi SM; Simberg D; Papini E; Farhangrazi ZS
Adv Drug Deliv Rev; 2020; 157():83-95. PubMed ID: 32389761
[TBL] [Abstract][Full Text] [Related]
8. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.
Gifford G; Vu VP; Banda NK; Holers VM; Wang G; Groman EV; Backos D; Scheinman R; Moghimi SM; Simberg D
J Control Release; 2019 May; 302():181-189. PubMed ID: 30974134
[TBL] [Abstract][Full Text] [Related]
9. Interrogation of Folic Acid-Functionalized Nanomedicines: The Regulatory Roles of Plasma Proteins Reexamined.
Wang H; Ding T; Guan J; Liu X; Wang J; Jin P; Hou S; Lu W; Qian J; Wang W; Zhan C
ACS Nano; 2020 Nov; 14(11):14779-14789. PubMed ID: 33084315
[TBL] [Abstract][Full Text] [Related]
10. Role of macrophage in nanomedicine-based disease treatment.
Song S; Xia H; Guo M; Wang S; Zhang S; Ma P; Jin Y
Drug Deliv; 2021 Dec; 28(1):752-766. PubMed ID: 33860719
[TBL] [Abstract][Full Text] [Related]
11. What are the biological and therapeutic implications of biomolecule corona formation on the surface of inhaled nanomedicines?
Kumar A; Forbes B; Mudway I; Bicer EM; Dailey LA
Nanomedicine (Lond); 2015 Feb; 10(3):343-5. PubMed ID: 25707971
[No Abstract] [Full Text] [Related]
12. Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth.
Moghimi SM
J Control Release; 2014 Sep; 190():556-62. PubMed ID: 24746624
[TBL] [Abstract][Full Text] [Related]
13. Material properties in complement activation.
Moghimi SM; Andersen AJ; Ahmadvand D; Wibroe PP; Andresen TL; Hunter AC
Adv Drug Deliv Rev; 2011 Sep; 63(12):1000-7. PubMed ID: 21689701
[TBL] [Abstract][Full Text] [Related]
14. Non-specific adsorption of complement proteins affects complement activation pathways of gold nanomaterials.
Quach QH; Kah JC
Nanotoxicology; 2017 Apr; 11(3):382-394. PubMed ID: 28287003
[TBL] [Abstract][Full Text] [Related]
15. The Nano-Bio Interactions of Nanomedicines: Understanding the Biochemical Driving Forces and Redox Reactions.
Wang Y; Cai R; Chen C
Acc Chem Res; 2019 Jun; 52(6):1507-1518. PubMed ID: 31149804
[TBL] [Abstract][Full Text] [Related]
16. CH(50): a revisited hemolytic complement consumption assay for evaluation of nanoparticles and blood plasma protein interaction.
Meerasa A; Huang JG; Gu FX
Curr Drug Deliv; 2011 May; 8(3):290-8. PubMed ID: 21291380
[TBL] [Abstract][Full Text] [Related]
17. Evaluating Nanomedicines: Obstacles and Advancements.
Swierczewska M; Crist RM; McNeil SE
Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles.
Vu VP; Gifford GB; Chen F; Benasutti H; Wang G; Groman EV; Scheinman R; Saba L; Moghimi SM; Simberg D
Nat Nanotechnol; 2019 Mar; 14(3):260-268. PubMed ID: 30643271
[TBL] [Abstract][Full Text] [Related]
19. Nanometer- and angstrom-scale characteristics that modulate complement responses to nanoparticles.
Moghimi SM; Haroon HB; Yaghmur A; Simberg D; Trohopoulos PN
J Control Release; 2022 Nov; 351():432-443. PubMed ID: 36152807
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicine and the complement paradigm.
Moghimi SM; Farhangrazi ZS
Nanomedicine; 2013 May; 9(4):458-60. PubMed ID: 23499667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
